Skip to main content
SpringerLink
Log in

IGFs in the Evaluation of Acromegaly

  • Chapter
The IGF System

Part of the book series: Contemporary Endocrinology ((COE,volume 17))

Abstract

Acromegaly is a condition of dysregulated growth hormone (GH) secretion characterized by excessive GH levels. Generally, acromegaly is the result of autonomous GH secretion, most often from a benign pituitary somatotropinoma, although rarely from GH-secreting pituitary carcinoma, ectopic pituitary tumors, or extrapituitary GH-producing tumors. Less frequently, acromegaly may be the result of excess GH-releasing hormone (GHRH) secretion from GHRH-producing tumors such as carcinoid or pancreatic islet cell tumors (1,2) Annual incidence estimates for acromegaly range from three to four cases per million persons, with a prevalence of 60–70 cases per million (2). Onset is insidious, typically resulting in a 10- to 15-yr delay after onset of GH hypersecretion before diagnosis is made. Acromegaly is associated with disfigurement, disability, and a two-to threefold increased mortality rate due to deaths from cardiac, respiratory, metabolic, or malignant complications (2) Early diagnosis and effective therapy are crucial to improve quality of life and normalize life expectancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Melmed S. Acromegaly. N Engl J Med 1990; 322: 966–77.

    PubMed  CAS  Google Scholar 

  2. Shimon I, and Melmed S. Acromegaly: differential diagnosis and treatment. In Wierman ME, ed. Contemporary Endocrinology, Vol 3: Diseases of the Pituitary: Diagnosis and Treatment. Humana Press, Totowa, NJ, 1997, pp. 135–151.

    Google Scholar 

  3. Clemmons DR, Van Wyk JJ, Ridgeway E, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin C. N Engl J Med 1979; 301: 1138–1142.

    PubMed  CAS  Google Scholar 

  4. Rinderknecht E, Humbel RE. Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum; isolation, chemical characterization, and some biological properties of forms I and II. Proc Natl Acad Sci USA 1976; 73: 2365–2369.

    PubMed  CAS  Google Scholar 

  5. Miller WL, Eberhardt NL. Structure and evaluation of growth hormone gene family. Endocrinol Rev 1983; 4: 97–130.

    CAS  Google Scholar 

  6. Berelowitz M, Szabo M, Frohman LA, Fireston S, Chu L, Hintz RL. Somatomedin-C mediates growth hormone negative feedback by effects on both hypothalamus and the pituitary. Science 1982; 212: 1279 1281.

    Google Scholar 

  7. Chen EY, Yu-Cheng L, Smith DH, Berrera-Saldana HA, Gelinas RE, Seeburg PH. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics 1989; 4: 479–497.

    PubMed  CAS  Google Scholar 

  8. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64: 51–58.

    PubMed  CAS  Google Scholar 

  9. Mayo KE, Vale W, Rivier J, Rosenfeld MG, Evans RM. Expression, cloning, and sequencing of a cDNA encoding human growth hormone-releasing factor. Nature 1983; 306: 86–88.

    PubMed  CAS  Google Scholar 

  10. Shen LP, Picket RL, Rutter WJ. Human somatostatin I: sequence of the cDNA. Proc Nat Acad Sci USA 1982; 79: 4575–4579.

    PubMed  CAS  Google Scholar 

  11. Yamada Y, Post SR, Wang K, Tager H, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Nat Acad Sci USA 1992; 89: 251–255.

    PubMed  CAS  Google Scholar 

  12. Schonbrunn A, Gu YZ, Dournard P, Beaudet A, Tannenbaum GS, Brown PJ. Somatostatin receptor subtypes: specific expression and signaling properties. Metab Clin Exp 1996; 45: 8–11.

    PubMed  CAS  Google Scholar 

  13. Shimon I, Yan X, Taylor JE, Weiss ML, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. J Clin Invest 1997; 100: 2386–2392.

    PubMed  CAS  Google Scholar 

  14. Reutens AT, Veldhuis JD, Hoffman DM, Leung KC, Ho KK. A highly sensitive growth hormone (GH) enzymed-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency. J Clin Endocrinol Metab 1996; 81: 1591–1597.

    PubMed  CAS  Google Scholar 

  15. van den Berg G, Frolich M, Veldhuis JD, Roelfsema F. Growth hormone secretion in recently operated acromegalic patients. J Clin Endocrinol Metab 1994; 79: 1706–1715.

    PubMed  Google Scholar 

  16. Herman-Bonert VS, Prager D, Melmed S. Growth hormone. In Melmed S, ed. The Pituitary. Blackwell Science, Inc. Cambridge, MA, 1995, pp. 98–135.

    Google Scholar 

  17. Hartman ML, Veldhuis JD, Thorner MO. Normal control of growth hormone secretion. Hormone Res 1993; 40: 37–47.

    PubMed  CAS  Google Scholar 

  18. Ho K, Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol 1994; 41: 75–83.

    CAS  Google Scholar 

  19. Veldhuis JD, Iranmanesh A. Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996; 19: S221 - S224.

    PubMed  CAS  Google Scholar 

  20. Jaffe CA, DeMott-Friberg R, Barkan AL. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist: direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest 1993; 92: 695–701.

    PubMed  CAS  Google Scholar 

  21. Plotsky PM, Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science 1985; 230: 461–463.

    PubMed  CAS  Google Scholar 

  22. Frohman LA, Downs TR, Clarke IJ, Thomas GB. Measurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanesthetized sheep. Spontaneous secretion and response to insulin-induced hypoglycemia. J Clin Invest 1990; 86: 17–24.

    PubMed  CAS  Google Scholar 

  23. Thonier MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, Johanson A, Vale W, Horvath E, Kovacs K. Somatotroph hyperplasia: successful treatment by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor (GRF). J Clin Invest 1982; 70: 965–977.

    Google Scholar 

  24. Losa M, Chiodini PG, Liuzzi A, Konig A, Muller OA, Schopohl J, von Werder K. Growth hormone releasing-hormone infusion in patients with active acromegaly. J Clin Endocrinol Metab 1986; 63: 88–93.

    PubMed  CAS  Google Scholar 

  25. Wood SM, Ch’ng JL, Adams EF, Webster JD, Joplin GF, Mashiter K, Bloom SR. Abnormalities of growth hormone release in response to human pancreatic growth hormone releasing factor (GRF (1–44)) in acromegaly and hypopituitarism. Br Med J 1983; 286: 1687–1691.

    CAS  Google Scholar 

  26. Lopes MB, Gaylinn BD, Thorner MO, Stoler MH. Growth hormone-releasing hormone receptor mRNA in acromegaly pituitary tumors. Am J Pathol 1997; 150: 1885–1891.

    PubMed  CAS  Google Scholar 

  27. Hartman ML, Veldhuis JD, Vance ML, Faria AC, Furlanetto RW, Thorner MO. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab 1990; 70: 1375–1384.

    PubMed  CAS  Google Scholar 

  28. Yamashita S, Weiss M, Melmed S. Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells. J Clin Endocrinol Metab 1986; 63: 730–735.

    PubMed  CAS  Google Scholar 

  29. Gil Ad I, Weizman A, Silbergeld A, Dickerman Z, Kaplan B, Laron Z, Koch Y. Differential effects of insulin-like growth factor-I and growth hormone on hypothalamic regulation of growth hormone secretion in the rat. J Endocrinol Invest 1996; 19: 542–547.

    Google Scholar 

  30. Sato M, Frohman LA. Differential effects of central and peripheral administration of growth hormone (GH) and insulin-like growth factor on hypothalamic GH-releasing hormone and somatostatin gene expression in GH-deficient dwarf rats. Endocrinology 1993; 133: 793–799.

    PubMed  CAS  Google Scholar 

  31. Uchiyama T, Kaji H, Abe H, Chihara K. Negative regulation of hypothalamic growth hormone-releasing factor messenger ribonucleic acid by growth hormone and insulin-like growth factor I. Neuroendocrinology 1994; 59: 411–450.

    Google Scholar 

  32. Bermann M, Jaffe CA, Tsai W, DeMott-Frieberg R, Barkan AL. Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin. J Clin Invest 1994; 94: 138–145.

    PubMed  CAS  Google Scholar 

  33. Epelbaum J, Moyse E, Tannenbaum GS. Combined autoradiographic and immunohistochemical evidence for an association of somatostatin binding sites with growth hormone-releasing factor-containing nerve cell bodies in the rat arcuate nucleus. J Neuroendocrinol 1989; 1: 109–116.

    PubMed  CAS  Google Scholar 

  34. Salmon WD Jr, Daughaday WH. A hormonally-controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825–836.

    PubMed  CAS  Google Scholar 

  35. Bell GI, Gerhard DS, Fong NM, Sanchez-Pescador K, Rall LB. Isolation of the human insulin-like growth factor genes: insulin-like growth factor II and insulin genes are contiguous. Proc Natl Acad Sci USA 1985; 82: 6450–6454.

    PubMed  CAS  Google Scholar 

  36. Schoenle E, Zapf J, Humbel RE, Froesch ER. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 1982; 296: 252–253.

    PubMed  CAS  Google Scholar 

  37. Pell JM, Bates PC. Differential actions of growth hormone and insulin-like growth factor I on tissue protein metabolism in dwarf mice. Endocrinology 1992; 130: 1942–1950.

    PubMed  CAS  Google Scholar 

  38. Green H, Morikawa M, Nixon T. A dual effector theory of growth hormone action. Differentiation 1985; 29: 195–198.

    PubMed  CAS  Google Scholar 

  39. Clemmons DR. Insulin-like growth factor binding proteins. TEM 1990; 1: 412–417.

    CAS  Google Scholar 

  40. Rajaram S, Baylink DL, Mohan S. Insulin-like growth factor binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801–831.

    PubMed  CAS  Google Scholar 

  41. Zapf J, Waldvogel M, Froesch ER. Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors in healthy adults. J Clin Invest 1986; 77: 1768–1775.

    PubMed  CAS  Google Scholar 

  42. Baumann G, Winter RJ, Shaw M. Circulating molecular variants of growth hormone in childhood. Pediatr Res 1987; 21: 21–22.

    Google Scholar 

  43. Cooke NE, Ray J, Watson MA, Estes PA, Kuo BA, Liebhaber SA. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns. J Clin Invest 1988; 82: 270–275.

    PubMed  CAS  Google Scholar 

  44. Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, Barnard R, Waters MJ, Wood WI. Growth hormone receptor and serum binding protein: purification, cloning, and expression. Nature 1987; 330: 537–543.

    PubMed  CAS  Google Scholar 

  45. Manner DA, Winer LM, Shaw MA, Baumann G. Plasma growth hormone (GH)-binding proteins: effect of GH binding to receptors and GH action. J Clin Endocrinol Metab 1991; 73: 30–34.

    Google Scholar 

  46. Furlanetto RW, Underwood LE, Van Wyk JJ, D’Ercole AJ. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977; 60: 648–657.

    PubMed  CAS  Google Scholar 

  47. Zapf J, Walther H, Froesch ER. Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest 1981; 68: 1321–1330.

    PubMed  CAS  Google Scholar 

  48. Wass JAH, Clemmons DR, Underwood LE, Barrow I, Besser GM, Van Wyk JJ. Changes in circulating somatostatin-C levels in bromocriptine-treated acromegaly. Clin Endocrinol (Oxf) 1982; 17: 369.

    CAS  Google Scholar 

  49. Stonesifer LD, Jordan RM, Kohler PO. Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response. J Clin Endocrinol Metab 1981; 53: 931–934.

    PubMed  CAS  Google Scholar 

  50. NortierJWR, Croughs RJM, Thijssen JHH, Schwartz F. Bromocriptine therapy in acromegaly: effects on plasma levels, somatomedin C levels and clinical activity. Clin Endocrinol (Oxf) 1985; 22: 209.

    Google Scholar 

  51. Clemmons DR, Underwood LE, Van Wyk JJ. Hormonal control of immunoreactive somatomedin production by cultured human fibroblasts. J Clin Invest 1981; 67: 10.

    PubMed  CAS  Google Scholar 

  52. Scott CD, Martin JL, Baxter RC. Rat hepatocyte insulin-like growth factor I and binding protein: effect of growth hormone in vitro and in vivo. Endocrinology 1985; 116: 1102.

    PubMed  CAS  Google Scholar 

  53. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-Usomatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988; 67: 69–73.

    PubMed  CAS  Google Scholar 

  54. Rieu M, Girard G, Bricaire H, Binoux M. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab 1982; 55: 147–153.

    PubMed  CAS  Google Scholar 

  55. Lamberts SWJ, Uitterlinden P, Verleum T. Relationship between growth hormone and somatomedinC levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with Sandostatin (SMS 201–995). Eur J Clin Invest 1987; 17: 354–359.

    PubMed  CAS  Google Scholar 

  56. Beck P, Parker ML, Daughaday WH. Paradoxical hypersecretion of growth hormone in response to glucose. J Clin Endocrinol Metab 1966; 26: 463–469.

    PubMed  CAS  Google Scholar 

  57. Gama R, Labib M, Teale JD, Marks V. Acromegaly with a misleading normal plasma insulin-like growth factor 1. Ann Clin Biochem 1989; 26: 102–103.

    PubMed  Google Scholar 

  58. Jaffe LS, Rosen HN. Normal insulin-like growth factor-I in an elderly woman with acromegaly and medical illness. Arch Intern Med 1994; 154: 1533–1535.

    PubMed  CAS  Google Scholar 

  59. Clemmons DR, Van Wyk JJ. Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab 1984; 13: 113–143.

    PubMed  CAS  Google Scholar 

  60. Luna AM, Wilson DM, Wibbelsman CJ, Brown RC, Nagashima RJ, Hintz RL, Rosenfeld RG. Somatomedins in adolescence: a cross-sectional study of the effect of puberty on plasma insulin-like growth factor I and II levels. J Clin Endocrinol Metab 1983; 57: 268–271.

    PubMed  CAS  Google Scholar 

  61. Yamamoto H, Sohmiya M, Oka N, Kato Y. Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. Acta Endocrinol 1991; 124: 497–500.

    PubMed  CAS  Google Scholar 

  62. Johanson AJ, Blizzard RM. Low somatomedin-C levels in older men rise in response to growth hormone administration. Johns Hopkins Med J 1981; 149: 115–117.

    PubMed  CAS  Google Scholar 

  63. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Muller J, Skakkebaek NE. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534–2542.

    PubMed  CAS  Google Scholar 

  64. Hintz RL, Suskind R, Amatayakul K, Thanangkul O, Olson R. Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. J Pediatr 1978; 92: 153–156.

    PubMed  CAS  Google Scholar 

  65. Clemmons DR, Klibanski A, Underwood E, McArthur JW, Ridgeway EC, Beitins IZ, Van Wyk JJ. Reduction in plasma immunoreactive somatomedin-C during fasting in humans. J Clin Endocrinol Metab 1981; 53: 1247–1250.

    PubMed  CAS  Google Scholar 

  66. Isley WL, Underwood LE, Clemmons DR. Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest 1983; 71: 175–182.

    PubMed  CAS  Google Scholar 

  67. Grzywa M. Serum somatomedin activity and growth hormone level in obese men: dependency on degree of obesity and hyperlipidemia. Exp Clin Endocrinol 1986; 88: 325–333.

    PubMed  CAS  Google Scholar 

  68. Copeland KC, Colletti RB, Devlin JT, McAuliffe TL. The relationship between insulin-like growth factor-I, adiposity, and aging. Metabolism 1990; 39: 584–587.

    PubMed  CAS  Google Scholar 

  69. Williams T, Berelowitz M, Joffe SN, Thomer MO, Rivier J, Vale W, Frohman LA. Impaired growth hormone responses to growth hormone-releasing factor in obesity. N Engl J Med 1984; 311: 1403 1407.

    Google Scholar 

  70. Blackard WG, Hull EW, Lopez A. Effect of lipids on growth hormone secretion in humans. J Clin Invest 1971; 50: 1439–1441.

    PubMed  CAS  Google Scholar 

  71. Fineberg SE, Horland AA, Merimee TJ. Free fatty acid concentrations and growth hormone secretion in man. Metabolism 1972; 21: 491–493.

    PubMed  CAS  Google Scholar 

  72. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol 1991; 35: 47–54.

    CAS  Google Scholar 

  73. Wu A, Grant DB, Hambley J, Levi AJ. Reduced serum somatomedin activity in patients with chronic liver disease. Clin Sci Mol Med 1974; 47: 359–366.

    PubMed  CAS  Google Scholar 

  74. Hirschberg R, Kaysen GA. Insulin-like growth factor I and its binding proteins in the experimental nephrotic syndrome. Endocrinology 1995; 136: 1565–1571.

    PubMed  CAS  Google Scholar 

  75. Tonshoff B, Powell DR, Zhao D, Durham SK, Coleman ME, Domene HM, Blum WF, Baxter RC, Moore LJ, Kaskel FJ. Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 1997; 138: 938–946.

    PubMed  CAS  Google Scholar 

  76. Weidemann E, Schwartz E. Suppression of growth hormone-dependent human sulfation factor by estrogen. J Clin Endocrinol Metab 1972; 34: 51–58.

    Google Scholar 

  77. Clemmons DR, Underwood LE, Ridgeway EC, Kliman B, Kjellberg RN, Van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement of metabolic status. Am J Med 1980; 69: 571–575.

    PubMed  CAS  Google Scholar 

  78. Whitelaw MJ. Experiences in treating excessive height in girls with cyclic oestradiol valerate; a ten year survey. Acta Endocrinol 1967; 54: 473–484.

    PubMed  CAS  Google Scholar 

  79. Wettenhall HNB, Cahill C, Roche AF. Tall girls: a survey of 15 years of management and treatment. J Pediatr 1975; 86: 602–610.

    PubMed  CAS  Google Scholar 

  80. Ross JL, Cassorla FG, Skerda MC, Valk IM, Loriaux DL, Cutler GB. A preliminary study on the effect of estrogen dose on growth in Turner’s syndrome. N Engl J Med 1983; 309: 1104.

    PubMed  CAS  Google Scholar 

  81. Cuttler L, Van Vliet G, Conte FA, Kaplan SL, Grumbach MM. Somatomedin-C levels in children and adolescents with gonadal dysgenesis: differences from age-matched normal females and effect of chronic replacement therapy. J Clin Endocrinol Metab 1985; 60: 1087.

    PubMed  CAS  Google Scholar 

  82. Barengolts EI, Kouznetsova T, Segalene A, Lathon P, Odvina C, Kukreja SC, Unterman TG. Effects of progesterone on serum levels of IGF-1 and on femur IGF-1 mRNA in ovariectomized rats. J Bone Min Res 1996; 11: 1406–1412.

    CAS  Google Scholar 

  83. Maes M, Underwood LE, Ketelslegers J-M. Low serum somatomedin-C in insulin-dependent diabetes: evidence for a post receptor mechanism. Endocrinology 1986; 118: 377–382.

    PubMed  CAS  Google Scholar 

  84. Phillips LS, Orawski AT. Nutrition and somatomedin. III. Diabetic control, somatomedin, and growth in rats. Diabetes 1977; 26: 864–869.

    PubMed  CAS  Google Scholar 

  85. Bereket A, Lang CH, Blethen SL, Ng LC, Wilson TA. Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children. Clin Endocrinol 1996; 45: 321–326.

    CAS  Google Scholar 

  86. Baxter RC. Radioimmunoassay of somatomedin-C: components with radioreceptor assay in patients with growth hormone disorders, hypothyroidism, and renal failure. Clin Chem 1982; 28: 488–495.

    PubMed  CAS  Google Scholar 

  87. Chernausek SD, Underwood LE, Utiger RD, Van Wyk JJ. Growth hormone secretion and plasma somatomedin-C in primary hypothyroidism. Clin Endocrinol 1983; 19: 337–344.

    CAS  Google Scholar 

  88. Dieguez C, Mallo F, Senaris R, Pineda J, Martul P, Leal-Cerro A, Pombo M, Casanueva FF. Role of glucocorticoids in the neuroregulation of growth hormone secretion. J Pediatr Endocrinol Metab 1996; 9: S255 - S260.

    Google Scholar 

  89. Gournielen M, Girard F, Binoux M. Serum somatomedin/insulin-like growth factor (IGF) and IGF carrier levels in patients with Cushing’s syndrome or receiving glucocorticoid therapy. J Clin Endocrinol Metab 1982; 54: 884–891.

    Google Scholar 

  90. Miell JP, Taylor AM, Jones J, Holly JM, Gaillard RC, Pralong FP, Ross RJ, Blum WF. The effects of dexamethasone treatment on immunoreactive and bioactive insulin-like growth factors (IGFs) and IGF binding protein in normal male volunteers. J Endocrinol 1993; 136: 525–533.

    PubMed  CAS  Google Scholar 

  91. Clemmons DR, Underwood LE, Ridgeway EC, Liman B, Van Wyk JJ. Hyperprolactinemia is associated with increased immunoreactive somatomedin-C in hypopituitarism. J Clin Endocrinol Metab 1981; 52: 731–735.

    PubMed  CAS  Google Scholar 

  92. Teale JD, Marks V. The measurement or insulin-like growth factor I: clinical applications and significance. Ann Clin Biochem 1986; 23: 413–424.

    PubMed  Google Scholar 

  93. Roelfsema F, Frolich M, Van Dulken H. Somatomedin-c levels in treated and untreated patients with acromegaly. Clin Endocrinol 1987; 26: 137–144.

    CAS  Google Scholar 

  94. Hulting A-L, Hall K, Werner S. Somatomedin A increments are diminished in acromegaly with concomitant hyper prolactinemia. Acta Endocrinol 1984; 106: 305–310.

    PubMed  CAS  Google Scholar 

  95. Furlanetto RW, Underwood LE, Van Wyk JJ, Handwerger S. Serum immunoreactive somatomedinC is elevated in late pregnancy. J Clin Endocrinol Metab 1979; 47: 695–697.

    Google Scholar 

  96. Hasegawa Y, Hasegawa T, Takada M, Tsuchiya Y. The free form of insulin-like growth factor I increases in circulation during normal human pregnancy. J Clin Endocrinol Metab 1995; 80: 32843286.

    Google Scholar 

  97. Rudman D, Mattson DE. Serum insulin-like growth factor I in healthy older men in relation to physical activity. J Am Geriatr Soc 1994; 42: 71–76.

    PubMed  CAS  Google Scholar 

  98. Kreamer WJ, Aguilera BA, Terada M, Newton RU, Lynch JM, Rosandaal G, McBride JM, Gordon SE, Hakkinen K. Responses of IGF-I to endogenous increases in growth hormone after heavy-resistance exercise. J Appl Phys 1995; 79: 1310–1315.

    Google Scholar 

  99. Vitiello MV, Wilkinson CW, Merriam GR, Moe KE, Prinz PN, Ralph DD, Colasurdo EA, Schwartz RJ. Successful 6-month endurance training does not alter insulin-like growth factor-I in healthy older men and women. J Gerontol 1997; 52: M149 - M154.

    CAS  Google Scholar 

  100. Di Luigi I, Conti FG, Casini A, Guidetti L, Zezza G, Pigozzi f, Spera G, Fortunio G, Romanelli F. Growth hormone and insulin-like growth factor I responses to moderate submaximal acute physical exercise in man: effects of octreotide, a somatostatin analogue, administration. Int J Sports Med 1997; 18: 257–263.

    PubMed  Google Scholar 

  101. Poehlman ET, Copeland KC. Influence of physical activity on insulin-like growth factor-I in healthy younger and older men. J Clin Endocrinol Metab 1990; 71: 1468–1473.

    PubMed  CAS  Google Scholar 

  102. Schwarz AJ, Brasel JA, Hintz RL, Mohan S, Cooper DM. Acute effect of brief low-and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II and IGF-binding protein-3 and its proteolysis in young healthy men. J Clin Endocrinol Metab 1996; 81: 3492–3497.

    PubMed  CAS  Google Scholar 

  103. Horner JM, Liu F, Hintz RL. Comparison of 1251-somatomedin-A and 125I-somatomedin-C radioreceptor assays for somatomedin peptide content in whole and acid-chromatographed plasma. J Clin Endocrinol Metab 1978; 47: 1287–1295.

    PubMed  CAS  Google Scholar 

  104. Daughaday WH, Mariz IK, Blethin SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab 1980; 51: 781–788.

    PubMed  CAS  Google Scholar 

  105. Barreca A, Ciccarelli E, Minuto F, Bruzzi P, Giordano G, Camanni F. Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol 1989; 120: 629635.

    Google Scholar 

  106. Acromegaly therapy consensus development panel. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 1994; 97: 468–473.

    Google Scholar 

  107. Barkan A. Controversies in the diagnosis and therapy of acromegaly. Endocrinologist 1997; 7: 300–307.

    Google Scholar 

  108. Dobrashian RD, O’Halloran DJ, Hunt A, Beardwell CG, Shalet SM. Relationships between insulin-like growth factor-I levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol 1993; 38: 589–593.

    CAS  Google Scholar 

  109. Earll JM, Sparks LL, Forsham PH. Glucose suppression of serum growth hormone in the diagnosis of acromegaly. JAMA 1967; 201: 134.

    Google Scholar 

  110. Jaquet P, Guibout M, Jaquet C, Grisoli F, Devolx BC, Dumas D, Bert J. Circadian regulation of growth hormone secretion after treatment in acromegaly. J Clin Endocrinol Metab 1980; 50: 322–328.

    PubMed  CAS  Google Scholar 

  111. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994; 78: 1312–1319.

    PubMed  CAS  Google Scholar 

  112. Thompson RG, Rodriguez A, Kowarski AA, Blizzard RM. Growth hormone: metabolic clearance rates, integrated concentrations and production rates in normal adults and the effect of prednisone. J Clin Invest 1972; 51: 3193–3199.

    PubMed  CAS  Google Scholar 

  113. Evans WS, Faria ACS, Christiansen E, Ho KY, Weiss J, Rogol AD, Johnson ML, Blizzard RM, Veldhuis JD, Thorner MO. Impact of intensive venous sampling on characterization of pulsatile GH release. Am J Physiol 1987; 252: E549 - E556.

    PubMed  CAS  Google Scholar 

  114. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994; 78: 1312–1319.

    PubMed  CAS  Google Scholar 

  115. Okuno A, Yano K, Itoh Y, Hashida S, Ishikawa E, Mohri Z, Murakami Y. Urine growth hormone determinations compared with other methods in the assessment of growth hormone secretion. Acta Paediatr Scand 1987; 337:Suppl. 74–81.

    Google Scholar 

  116. Lunt H, Tucker AJ, Bullen H, Gibbs C, Wilkin TJ. Overnight urinary growth hormone measurement in the diagnosis of acromegaly. Clin Endocrinol 1990; 33: 205–212.

    CAS  Google Scholar 

  117. Main KM, Lindholm J, Vandeweghe M, Skakkebaek NE. Urinary growth hormone excretion in acromegaly: diagnostic value in mild disease activity. Acta Endocrinol 1993; 129: 409–413.

    PubMed  CAS  Google Scholar 

  118. Sukegawa I, Hizuka N, Tanako K, Asakawa K, Horikawa R, Hashida S, Ishikawa E, Mohri Z, Murakami Y, Shizuma K. Urinary growth hormone (GH) measurements are useful for evaluating endogenous GH secretion. J Clin Endocrinol Metab 1988; 66: 1117–1123.

    Google Scholar 

  119. Girard J, Celniker A, Price A, Tanaka T, Walker J, Welling K, Albertsson-Wikland K. Urinary measurement of growth hormone secretion. Acta Paediatr Scand Suppl 1989; 366: 149–154.

    Google Scholar 

  120. Winer LM, Shaw MA, Baumann G. Urinary growth hormone excretion rates in normal and acromegalic man: a critical appraisal of its potential clinical utility. J Endocrinol Invest 1989; 12: 461–467.

    PubMed  CAS  Google Scholar 

  121. Hanssen KF, Rasmussen P. Urinary growth hormone in acromegaly. Acta Med Scand 1974; 195: 381–384.

    PubMed  CAS  Google Scholar 

  122. Pholsena M, Le Bouc Y, Rousseau E, Christol R, Birman P, Perin L, Girard F. Evaluation of acromegaly by measurement of 24-hourly urinary growth hormone excretion. Acta Endocrinol 1993; 128: 9–14.

    PubMed  CAS  Google Scholar 

  123. Evans AJ, Willis DS, Wood PJ. The assay of urinary growth hormone in normal and acromegalic adults. Clin Endocrinol 1991; 35: 413–418.

    CAS  Google Scholar 

  124. Hattori N, Kato Y, Murakami Y, Hashida S, Ishikawa E, Mohri Z, Imura H. Urinary growth hormone levels measured by ultrasensitive enzyme immunoassay in patients with renal insufficiency. J Clin Endocrinol Metab 1988; 66: 727–732.

    PubMed  CAS  Google Scholar 

  125. Hattori N, Shimatsu A, Kato Y, Koshiyama H, Ishikawa Y, Tanoh T, Assadian H, Imura H. Urinary excretion of human growth hormone: daily variation and relationship with albumin and al-microglobulin in urine. Acta Endocrinol 1989; 121: 533–537.

    PubMed  CAS  Google Scholar 

  126. Grinspoon S, Clemmons D, Swearingen B, Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995; 80: 927–932.

    PubMed  CAS  Google Scholar 

  127. Rasat R, Livesey JL, Espiner EA, Abbott GD, Donald RA. IGF-I and IGFBP-3 screening for disorders of growth hormone secretion. NZ Med J 1996; 109: 156–159.

    CAS  Google Scholar 

  128. de Herder WW, van der Lely AJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol 1995; 43: 501–505.

    Google Scholar 

  129. Paramo C, Andrade OM, Fluiters E, Luna R, de la Fuente J, Garcia-Mayor RV. Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-UIGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Metab Clin Exp 1997; 46: 494–498.

    PubMed  CAS  Google Scholar 

  130. Thissen JP, Ketelslegers JM, Maiter D. Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults. Growth Regul 1996; 6: 222–229.

    PubMed  CAS  Google Scholar 

  131. Clemmons DR, Thissen JP, Maes M, Ketelslegers JM, Underwood LE. Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or protein-deprived rats induces specific IGF-binding proteins in serum. J Clin Endocrinol Metab 1989; 125: 2967–2972.

    CAS  Google Scholar 

  132. Irie M, Tsushima T. Increase in serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. J Clin Endocrinol Metab 1972; 35: 97–100.

    PubMed  CAS  Google Scholar 

  133. Shibasaki T, Hotta M, Masuda A, Imaki T, Obara N, Hizuka N, Takanok, Wakabayashi I, Demura H, Ling N. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly. J Clin Endocrinol Metab 1986; 63: 167–173.

    CAS  Google Scholar 

  134. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992; 21: 713–735.

    PubMed  CAS  Google Scholar 

  135. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cooke DM. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Int Med 1992; 117: 711–718.

    PubMed  CAS  Google Scholar 

  136. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995; 80: 2768–2775.

    PubMed  CAS  Google Scholar 

  137. Lamberts SWJ, Uitterlinden P, Schuijff PC, Klijn JGM. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical “cure. ” Clin Endocrinol 1988; 29: 411–420.

    CAS  Google Scholar 

  138. Kao PC, Laws ER Jr, Zimmerman D. Somatomedin C/insulin-like growth factor I levels after treatment of acromegaly. Ann Clin Lab Sci 1992; 22: 95–99.

    PubMed  CAS  Google Scholar 

  139. Jorgensen JOL, Moller N, Lauritzen T, Christiansen JS. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 1990; 70: 1616–1623.

    PubMed  CAS  Google Scholar 

  140. Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkin AL. Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 1994; 78: 1403–1410.

    PubMed  CAS  Google Scholar 

  141. Semer M, Faria AC, Nery M, Salgado LR, Knoepfelmacher M, Wajchenberg BL, Liberman B. Growth hormone pulsatility in active and cured acromegalic subjects. J Clin Endocrinol Metab 1995; 80: 37673770.

    Google Scholar 

  142. Daughaday WH. A personal history of the origin the somatomedin hypothesis and recent challenges to its validity. Perspect Biol Med 1989; 39: 194–211.

    Google Scholar 

  143. Melmed S, Yamashita S, Yamasaki H, Fagin J, Namba H, Yamamoto H, Weber M, Morita S, Webster J, Prager D. IGF-I receptor signalling: lessons from the somatotroph. Recent Prog Horm Res 1996; 51: 189–216.

    PubMed  CAS  Google Scholar 

  144. Celniker AC, Chen AB, Wert RM, Sherman BM. Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989; 68: 469–476.

    PubMed  CAS  Google Scholar 

  145. Bowsher RR, Apathy JM, Ferguson AL, Riggin RM, Henry DP. Cross-reactivity of monomeric and dimeric biosynthetic human growth hormone in commercial immunoassays. Clin Chem 1990; 36: 362–366.

    PubMed  CAS  Google Scholar 

  146. Blethen SL, Chasalow FI. Use of a two-site immunoradiometric assay for growth hormone (GH). J Clin Endocrinol Metab 1983; 57: 1031–1035.

    PubMed  CAS  Google Scholar 

  147. Reiter EO, Morris AH, MacGillivray MH, Weber D. Variable estimates of serum growth hormone concentrations by different radioassay systems. J Clin Endocrinol Metab 1988; 66: 68–71.

    PubMed  CAS  Google Scholar 

  148. Jan T, Shaw MA, Baumann G. Effects of growth hormone-binding proteins on serum growth hormone measurements. J Clin Endocrinol Metab 1991; 71–2: 387–391.

    Google Scholar 

Download references

Authors
  1. Marlys R. Drange MD, PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shlomo Melmed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, OR, USA

    Ron G. Rosenfeld MD

  2. Oregon Health Sciences University, Portland, OR, USA

    Charles T. Roberts Jr. PhD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Drange, M.R., Melmed, S. (1999). IGFs in the Evaluation of Acromegaly. In: Rosenfeld, R.G., Roberts, C.T. (eds) The IGF System. Contemporary Endocrinology, vol 17. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-712-3_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-712-3_29

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-138-7

  • Online ISBN: 978-1-59259-712-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation